Overcoming Challenges in the Clinical and Economic Management of Primary Immunodeficiency Diseases (PIDD): What Does Managed Care Need to Know About Immunoglobulin Replacement Therapy?

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2019 to January 31, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
CSL Behring and Shire

Primary immunodeficiency diseases (PIDD) represent a myriad of life-long conditions that result when a component of the immune system is absent or does not function properly due to a primary or inherited defect. The primary treatment for these patients with antibody deficiencies is lifetime administration of immunoglobulin replacement therapy; a therapeutic substance derived from human blood plasma and made up of immunoglobulin. Since Ig only replaces the missing end product but does not correct the patient’s defect in antibody production, Ig replacement is usually necessary for the patient’s lifetime. Although approximately 150,000 patients are likely to benefit from Ig replacement, only an estimated 35,000 to 55,000 receive ongoing therapy. A lack of awareness and depth of understanding contribute to this underserved population of individuals with PI. This presentation will explore the available immunoglobulin replacement therapy options, the economic burden of undertreatment and strategies for improving patient outcomes and quality of life.

Upon completion of this activity, participants will be able to:

  • List early signs and symptoms of primary immunodeficiency (PIDD), and employ appropriate techniques to identify patients with PIDD

  • Analyze the mechanisms of action, efficacy, and safety profiles of current and emerging immunoglobulin (Ig) replacement therapies and strategies for their use in PIDD

  • Individualize treatment plans with a focus on patient- and disease-related factors unique to PIDD

  • Describe key pharmacoeconomic studies pertaining to Ig replacement therapy and the budgetary implications of these data in a managed care framework

  • Examine the total cost of care for PIDD, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs

  • Apply methods to enable optimal cost management of Ig replacement therapies to be realized by multiple PIDD stakeholders including managed care organizations

Faculty: Richard Wasserman, MD, PhD
Medical Director of Pediatric Allergy and Immunology
Medical City Children’s Hospital


Dr. Wasserman serves on an advisory board for Grifols and Shire. He serves as a consultant for Korean Green Cross, Shire, and Therapure. He has received research/grant support from CSL Behring, Korean Green Cross, Octapharma, Prometic, Shire, and Therapure. He serves on the speaker's bureau for CSL Behring and Shire. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
CSL Behring and Shire

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue